Published on 01/12/2025

Closed System Design: Mapping Open-to-Closed Opportunities

The advancement of biologics and advanced therapies medicinal products (ATMPs) mandates thorough validation processes to ensure their safety and efficacy. A key aspect of this validation is maintaining the integrity of the closed systems and aseptic controls involved. Closed System Design focuses on mapping the transition from open systems to closed environments to mitigate contamination risks and assure product quality. This guide offers a detailed, step-by-step approach to closed system design and validation, aligned with regulatory expectations from agencies like the FDA, EMA, MHRA, and PIC/S.

Understanding Closed Systems and Aseptic Controls

Closed systems are defined as systems that prevent the entry of contaminants during the manufacturing process, essentially ensuring a controlled environment. In the context of biotechnology and pharmaceuticals, these systems are crucial for the production of sterile products, especially when it involves live cells or viruses.

Aseptic controls are measures taken within such systems to protect the product from microbial contamination. The administration of sterile processes is dictated by guidelines such as Aseptic Controls Annex 1, which outlines the requirements for aseptic manufacturing and emphasizes the importance of maintaining sterility throughout the production lifecycle.

This section provides an overview of key concepts related to closed systems in aseptic processing:

• Definition: A closed system utilizes barriers to control and limit exposure to the external environment.
• Closed vs Open Systems: Open systems allow environmental exposure, increasing the risk of contamination, while closed systems are designed to manage and mitigate these risks effectively.
• Role of Single-Use Systems: Single-use systems further reduce the need for cleaning validation, improving efficiency and product safety by eliminating cross-contamination.
• Spiking Studies: These studies are essential for establishing the effectiveness of viral clearance validation in closed systems.
• Regulatory Guidance: Familiarity with relevant regulations, including ICH Q5A(R2), is critical for compliance in validation efforts.

Step-by-Step Guide to Closed System Design

The design and validation of closed systems tailored for aseptic production require systematic planning and execution. The following sections outline a comprehensive approach to closed system design and its validation processes.

Step 1: Risk Assessment and Identification of Opportunities

The first step in closed system design involves conducting a risk assessment to identify potential contamination points within the production environment. This assessment should focus on:

• Environmental Risks: Evaluating the risks posed by air quality, surface contamination, and personnel interactions.
• Product Risks: Understanding how product characteristics influence susceptibility to contamination.
• Process Risks: Identifying how each phase of production may introduce risks requiring mitigation.

By identifying vulnerabilities, teams can leverage these insights to design improved closed systems that enhance aseptic processing. The assessment should utilize standardized methodologies, such as Failure Mode and Effects Analysis (FMEA), to ensure a robust approach.

Step 2: Designing Closed Systems and Single-Use Systems

With the risk assessment in hand, the next step is designing the closed system components, which may include isolators, controlled environments, and single-use systems. The design should prioritize:

• Material Selection: The use of materials that are compatible and do not leach harmful substances into the product.
• Integration: Seamless integration of equipment and processes to limit transfer points that can introduce risk.
• Configurability: Developing systems that can be adapted based on varying production requirements or changes in regulations.
• Scalability: Ensuring that the design can accommodate various scales of operations without compromising integrity.

This design phase also includes drafting process flow diagrams that illustrate material flows and equipment placement, facilitating robust validation planning.

Step 3: Validation Planning

Validation is a critical step in establishing the reliability and efficacy of closed systems. A comprehensive validation plan should include:

• Validation Objectives: Clearly defined goals for the validation effort, including assessing the effectiveness of aseptic controls.
• Process Performance Qualification (PPQ): Detailed strategies for performance qualification tailored to each specific closed system, ensuring compliance with manufacturer and regulatory standards.
• Validation Master Plan (VMP): A structured approach to the overall validation that includes timelines, resources, and responsibilities.

Validation planning also involves establishing Chain of Identity/Custody (COI/COC) protocols to ensure traceability throughout the production lifecycle. This step is paramount in maintaining the integrity of products, especially those derived from living systems.

Step 4: Executing Validation Activities

Executing validation activities involves rigorous testing and documentation. Critical components of this phase include:

• Qualification Testing: Executing Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) to ensure that all systems operate as intended.
• Viral Clearance Validation: Conducting comprehensive studies to validate the effectiveness of viral removal processes, utilizing appropriate spiking studies to demonstrate capability.
• Documentation: Creating detailed records for all tests, results, and observations to maintain compliance with regulatory expectations.

It is essential to involve cross-functional teams during these activities to ensure that all perspectives are considered and that best practices are followed across the board.

Step 5: Continuous Monitoring and Control

Once the systems have been validated, continuous monitoring is required to ensure consistent control of the manufacturing environment. This includes:

• Environmental Monitoring: Regular assessments of air quality and surface cleanliness to prevent contamination.
• Product Monitoring: Continuous assessment of product potency and identity critical quality attributes (CQAs) to ensure ongoing compliance with specifications.
• Change Control Procedures: Implementing formal procedures to manage any changes affecting validated systems to preserve the validation status.

A robust approach to continuous monitoring not only ensures compliance with ongoing regulatory demands but also fosters a culture of quality within production operations.

Conclusion: Embracing Innovation in Closed System Design

The landscape of pharmaceutical development, particularly in the realms of biologics and ATMPs, is increasingly dependent on meticulously designed closed systems. By conducting thorough risk assessments, carefully designing closed and single-use systems, and adhering to rigorous validation protocols, pharmaceutical professionals can mitigate contamination risks while ensuring product quality and patient safety.

Ultimately, embracing closed system design not only aligns with regulatory expectations but also empowers organizations to innovate in safer, more efficient ways. As regulatory guidelines such as ICH Q5A(R2) evolve, staying ahead through continuous learning and improvement in validation processes remains the cornerstone of successful aseptic operations.